Overview of Codeintropfen-CT

Property	Description
Active ingredient	Codeine (as a salt)
Form	Oral Solution (Tropfen)
Pharmacological class	Opioid Analgesic and Antitussive
General purpose	Suppression of dry cough and mild pain relief
Origin	Natural Opium Alkaloid Derivative

What Type of Medicine is Codeintropfen-CT?

Codeintropfen-CT is a specific medicinal preparation containing the active ingredient Codeine, which is classified pharmacologically as both an Opioid Analgesic and a potent Antitussive. This compound is a natural opium alkaloid derivative, fundamentally placing the product within the opiate family. Codeine acts centrally to relieve pain and suppress cough, supporting its dual classification. The necessity for the product to be categorized as a prescription-only medicine reflects the centrally-acting nature of the compound. As a single-ingredient product, Codeintropfen-CT's therapeutic profile is defined exclusively by the established actions of Codeine, which are utilized for managing specific, centrally mediated symptoms.

Form and Composition: Why Codeintropfen-CT is a Solution

The product is supplied in the specialized dosage form known as Tropfen (drops), which denotes an Oral Solution intended for consumption by mouth, a feature often preferred for flexibility in administration. This liquid preparation consists of the active substance, Codeine (typically provided as a highly soluble salt such as phosphate or sulfate), dissolved within an aqueous/ethanolic vehicle. As an approved solution containing Codeine salt, the preparation is defined by this specific composition and form. The solution format is a distinguishing characteristic, allowing for precise titration unlike fixed-dose solid preparations.

What is the General Purpose of Codeine Drops?

The general purpose of Codeintropfen-CT is to manage persistent, non-productive dry cough and provide foundational mild-to-moderate pain relief. The mechanism relies on Codeine acting as a prodrug that is converted in the body into the more potent opioid derivative, Morphine, which then acts on the Central Nervous System (CNS). This systemic effect specifically targets the medullary cough center in the brain, effectively dampening the central reflex responsible for the drive to cough. This makes the drops useful in situations where persistent coughing is disruptive, such as during the night or periods of extended rest.

Regulatory References

What side effects are possible with Codeintropfen-CT?

Possible Side Effects and Safety Information

The safety profile of Codeintropfen-CT, which contains the opioid derivative Codeine, is defined by regulatory documents detailing the potential for adverse reactions and specific usage restrictions.

Documented Adverse Reactions

The most frequently documented adverse reactions, classified as Most Common in official labeling, are primarily related to the central nervous and gastrointestinal systems. These include drowsiness, light-headedness, dizziness, sedation, nausea, vomiting, sweating, and constipation. Other documented reactions include pruritus (itching) and confusion. Adverse reactions are grouped by system-organ class, with effects noted across the nervous system, respiratory system, and gastrointestinal tract.

Serious Safety Considerations

Official regulatory information emphasizes the risk of life-threatening respiratory depression, which is the most critical serious adverse reaction associated with opioid use. The risk for this event is highest during treatment initiation or following a dose increase. Serious risks also include Severe Hypotension and the potential for Serotonin Syndrome when used alongside certain other medications.

Population-Specific Restrictions and Safety Patterns

Regulatory authorities have established explicit safety limitations for specific groups. Codeine is contraindicated in children younger than 12 years of age for any use, and also in adolescents under 18 following tonsillectomy or adenoidectomy. It is similarly contraindicated in breastfeeding mothers and in individuals known to be CYP2D6 ultra-rapid metabolizers due to the heightened risk of toxicity. Prolonged use during pregnancy carries the official risk of Neonatal Opioid Withdrawal Syndrome in the newborn. Safety restraints also apply to patients with certain pre-existing conditions, such as acute bronchial asthma or gastrointestinal obstruction, including paralytic ileus.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Documented overdose presentations: Overdose manifestations center on the opioid triad: acute respiratory depression (slow, shallow, or no breathing), profound CNS depression leading to coma or extreme somnolence, and miosis (pinpoint pupils). Other signs listed in regulatory documents include cyanosis (bluish skin discoloration), severe hypotension (low blood pressure), cold and clammy skin, and a weak pulse.

Physiological systems affected (as stated in label): Central Nervous System, Respiratory System, Cardiovascular System.

Dose-related or exposure-related factors (if applicable): Regulatory labeling explicitly notes that accidental ingestion of even one dose can result in a fatal overdose.

Population-specific overdose notes (if applicable): The risk of fatal respiratory depression is particularly highlighted in children from accidental ingestion. The risk is also increased in elderly or severely debilitated patients.

Emergency-response statements (as written in official documents): Naloxone is the specified opioid antagonist for reversal. Documented supportive measures include activated charcoal, intravenous (IV) fluids, and necessary breathing support (e.g., ventilation).

When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention and Call 911 (or local emergency services) immediately upon suspicion of overdose, or if signs of confusion, small pupils, or respiratory distress are observed.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): Life-threatening, Fatal.

Regulatory basis (EMA / FDA / etc.): FDA (U.S. Food and Drug Administration), NIH/MedlinePlus.

Overdose-context constraints (as defined in official documents): Accidental ingestion, vulnerable populations.

Resulting Overdose Structure

Official overdose statements:

Life-Threatening Respiratory Depression, coma, and death are documented severe outcomes of overdose.
Regulators mandate that Naloxone is used for the reversal of opioid-induced respiratory depression.
Immediate action requires contacting emergency services.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile for this product by focusing strictly on the potential for acute, severe central nervous system and respiratory depression. This profile establishes a clear mandate for immediate emergency medical intervention upon suspicion of overdose, due to the recognized risk of life-threatening respiratory compromise and fatal outcomes.

Therapeutic Uses of Codeintropfen-CT

Codeintropfen-CT (Codeine oral solution) is commonly used in situations involving certain distressing symptoms, applied across domains where short-term symptomatic assistance is needed to manage noticeable symptom manifestations. The active ingredient is considered relevant for both pain relief and cough suppression.

Managing Disruptive, Non-Productive Cough

The medication is commonly used to address irritant cough patterns characterized by a dry, hacking nature that creates noticeable interference, especially with rest. It is applied in addressing the intensity and frequency of the pronounced urge to cough, providing support that helps ease the overall symptom burden of this disruptive symptom. This relief supports the patient during difficult episodes by easing distress that may interfere with rest.

Quick Fact: Relief for Irritant Cough Codeintropfen-CT is commonly used to help with cough symptoms that become more disruptive during flare-ups and create noticeable physiological strain.

Relief from Acute Mild to Moderate Pain

Codeintropfen-CT is also applied in clinical settings marked by the onset of mild to moderate acute pain. It offers a foundation of analgesic support used when symptoms cluster into patterns requiring short-term supportive management, such as discomfort following minor medical procedures or during episodes of sudden symptomatic escalation. This offers symptomatic relief that may assist with maintaining functional stability when symptoms are more noticeable.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Codeintropfen-CT (containing codeine phosphate monohydrate) is a prescription medication primarily used as a cough suppressant. Its use is limited to certain populations due to the risk of serious side effects, including respiratory depression.

Who Can Use It (Indications)

Codeintropfen-CT is typically used for the short-term relief of a dry, non-productive cough in adults and adolescents aged 12 years and older when the underlying cause of the cough has been identified and other treatments are insufficient.

Who Cannot Use It (Contraindications)

This medication is contraindicated and must not be used in the following individuals or circumstances:

Contraindication Category	Examples/Conditions
Age	Children under 12 years of age.
Allergy	Known hypersensitivity to codeine or any other component (e.g., sodium metabisulfite)
Breathing/Lungs	Acute asthma attack, severe breathing problems, respiratory depression, or during childbirth/imminent premature birth.
Metabolism/Other	Patients known to be ultra-rapid metabolizers of codeine to morphine.
Pregnancy/Breastfeeding	Breastfeeding mothers and women in the final stage of pregnancy or with imminent premature birth.

Caution is required for elderly patients and those with head injuries, increased intracranial pressure, specific digestive tract obstructions (e.g., paralytic ileus), or chronic liver or kidney disease. Alcohol should be avoided during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Codeine's interaction profile is primarily governed by its metabolism in the liver. Codeine is a prodrug that must be converted into its active metabolite, morphine, to produce its therapeutic effects. This conversion is predominantly carried out by the liver enzyme Cytochrome P450 2D6 (CYP2D6).

Pharmacokinetic Interactions

Interactions involving Codeintropfen-CT are most often related to substances that alter the activity of the CYP2D6 enzyme. CYP2D6 inhibitors (medicines that slow down the enzyme) can decrease the conversion of codeine to morphine, potentially leading to reduced analgesic efficacy. Conversely, CYP2D6 inducers (medicines that increase the enzyme's activity) may accelerate this conversion. This can lead to increased concentrations of morphine, raising the risk of opioid-related adverse effects.

Population-Specific Efficacy

The presence of genetic variations in the CYP2D6 gene is a critical consideration. Individuals classified as CYP2D6 poor metabolizers have significantly impaired enzyme function and may experience little to no pain relief from codeine because they cannot efficiently convert it to morphine. In contrast, ultra-rapid metabolizers have multiple copies of the gene, leading to excessively fast conversion and a higher risk of adverse reactions due to rapid accumulation of morphine. Consult a healthcare professional about potential interactions and your individual metabolic profile.

Mechanism of Action

How Codeintropfen-CT Works

Codeintropfen-CT's mechanism involves modulating the opioid receptor systems in the central nervous system. The active components act as agonists at mu-opioid receptors ( MOR), initiating a signal cascade that dampens neuronal excitability. This targeted effect occurs predominantly within the brainstem's cough center, where it modulates the excessive or overactive physiological response, influencing the cough threshold.

Codeine itself is largely a prodrug; its full mechanistic activity is contingent upon its conversion into the active metabolite, morphine. This process is catalyzed by the Cytochrome P450 2D6 ( CYP2D6) enzyme system. The conversion results in a metabolite with high affinity for the target receptors, supporting the subsequent modulation of pathway activity. The MOR engagement leads to changes in second messenger systems (like cAMP) and ion channel activity, modifying molecular steps that shape systemic physiological outcomes. This interference modulates overactive signaling within the targeted neural pathways, resulting in an adjustment of the cough response threshold.

Dosage and Administration Information

Administration Scope

Feature	Official Instruction
Route of administration	The sole approved method is the oral route for this liquid solution.
Dosing schedule (Antitussive)	Single Dose: 15 mg to 44 mg of Codeine. Maximum Daily Dose: 200 mg.
Dosing schedule (Analgesic)	Single Dose Range: 15 mg to 60 mg. Maximum Daily Dose: 360 mg.
Timing in relation to meals	Can be taken with or without food.
Preparation requirements	The oral solution is ready-to-use; it may be consumed undiluted or diluted in water.
Age-group administration rules	Contraindicated for children under 12 years. Not recommended for adolescents (12-18 years) with compromised respiratory function. Reduced dose may be necessary for older adults.
Missed-dose rules	If a dose is missed, take it when remembered, or skip it if it is nearly time for the next scheduled dose; do not take double doses.
Special procedural conditions	A calibrated measuring device must be used for accurate dosing. The lowest effective dosage must be used for the shortest duration. The final daily dose for cough is often taken in the evening before sleep.

Instruction Classifications

Feature	Classification / Constraint
Administration method type	Oral (Liquid Solution)
Frequency pattern	As-needed/Regularly Scheduled (e.g., Every 4, 6, or 8 hours, depending on indication)
Regulatory basis	Standard pharmaceutical specifications
Use-context constraints	Duration-limited; for acute pain relief, use should be limited to the minimum time required.

Resulting Procedural Structure

Official step sequence:

Measure: The liquid dose must be measured precisely using a calibrated device.
Ingest: The solution is taken via the oral route, with or without food.
Schedule: Doses are taken at specified intervals, such as every four hours for pain or six to eight hours for cough.
Limit: The maximum daily doses must not be exceeded, and use must be for the shortest necessary duration.
Discontinue: Cessation of therapy, especially following extended use, requires a gradual reduction (tapering) of the dose.

Connection to the overall use protocol: The established protocol dictates that Codeintropfen-CT must be precisely measured and ingested via the oral route, adhering to strict minimum intervals and maximum daily doses. The instructions mandate that the dose is kept at the lowest effective level and that the total duration of use remains limited. For discontinuation in physically dependent patients, the protocol requires a specific tapering process.

Recent Clinical Evidence

Recent Clinical Evidence: Codeintropfen-CT

Codeine is an opioid agent traditionally studied for its antitussive (cough-suppressant) properties, which are thought to be mediated centrally in the brain's cough center. The body converts a small fraction of codeine into morphine via the liver enzyme CYP2D6.

Efficacy and Study Limitations

Research on codeine as an antitussive agent in adults has yielded conflicting results. While some older studies reported efficacy, several recent, well-designed randomized controlled trials (RCTs) involving adults with acute cough due to upper respiratory tract infection found no statistically significant difference between codeine and a placebo in reducing cough frequency or severity.

Evidence of efficacy for codeine in treating short-term (acute) cough is considered limited by several regulatory and medical bodies. There is some limited evidence suggesting an effect in cases of chronic cough (lasting over 8 weeks).

Safety Considerations and Variability

Clinical data highlight significant inter-individual variability in response to codeine. This variability is linked to genetic differences in the CYP2D6 enzyme, which is responsible for converting codeine into its active form, morphine.

Ultra-rapid Metabolizers (UMs): Individuals who convert codeine to morphine faster than normal may have increased levels of morphine, which heightens the risk for serious adverse effects, including respiratory depression (slowed breathing).
Poor Metabolizers (PMs): Individuals who convert codeine to morphine slowly may not experience the expected therapeutic effect.

Due to this variability and the potential for serious risk, particularly concerning respiratory function, regulatory agencies have introduced restrictions on the use of codeine, especially in pediatric and certain adolescent populations, based on available safety and limited efficacy data.

Key Studies & References Systematic review of randomized controlled trials of over the counter cough medicines for acute cough in adults

Frequently Asked Questions (FAQ)

Common questions about Codeintropfen-CT (FAQ)

Q: What is the main difference between Codeintropfen-CT and other common cough suppressants?

A: The official classification for the active ingredient is as an opioid analgesic and a potent antitussive (cough suppressant). This means its action is primarily central, working in the brain to influence the cough threshold. Other types of cough medicines may work locally or through different mechanisms.

Q: How long does Codeintropfen-CT typically stay in your system after the last dose?

A: The active substance has an approximate half-life of three hours, according to official pharmacokinetic information. The short half-life helps determine the drug's dosing frequency specified on the label.

Q: Can Codeintropfen-CT be used for a cough caused by seasonal allergies or post-nasal drip?

A: Official product information states that this medicine is indicated for a dry, non-productive cough when the cause has been identified and the cough is not responding to other treatments. The regulatory documents do not specifically list allergic or post-nasal drip cough as target indications.

Q: Does Codeintropfen-CT offer any relief for a sore throat accompanying a cough?

A: The active ingredient is classified for the suppression of cough and for mild-to-moderate pain relief. While this analgesic function is noted in official documents, sore throat is not explicitly named as a treatable indication in the official prescribing information.

Q: What are the potential signs of a serious or severe reaction to Codeintropfen-CT?

A: Regulatory warnings highlight the risk of serious reactions, including life-threatening respiratory depression (very slow or shallow breathing) and severe hypotension (marked dizziness or fainting). The official documentation states that if these signs occur, immediate emergency medical attention should be sought.

Q: How common is the potential for dependence or withdrawal symptoms when stopping Codeintropfen-CT?

A: As an opioid derivative, this medicine carries a documented risk of developing physical dependence and tolerance, even when used for short periods. Official documents emphasize the need for a gradual reduction (tapering) of the dose if the medicine has been used for an extended duration.

Q: Are there risks associated with the long-term or chronic use of Codeintropfen-CT?

A: Official guidance mandates that this medicine be limited to the shortest possible duration necessary to treat the symptom. Prolonged or chronic use significantly increases the documented risk of developing physical dependence and may lead to withdrawal symptoms upon cessation.

Q: Are children more likely to experience side effects from Codeintropfen-CT?

A: Regulatory documents have introduced strict contraindications for this medicine in children under 12 years of age. This restriction is based on the increased risk of serious, life-threatening adverse reactions, particularly respiratory depression, linked to individual differences in how the drug is metabolized.

Q: What should be done if too much Codeintropfen-CT is used accidentally?

A: The official documents classify acute overdose as a medical emergency for which immediate medical attention or contact with emergency services is required. This is due to the potential for serious adverse effects on the respiratory system.

Q: Can Codeintropfen-CT be taken with common over-the-counter painkillers?

A: Regulatory guidance advises caution when taking this medicine alongside other substances, especially those that can cause sedation or respiratory depression. Although some common over-the-counter painkillers may be allowed, regulatory sources advise patients to consult a healthcare professional regarding all co-administered medications.

Q: What happens if I take Codeintropfen-CT with sleeping pills?

A: Official warnings explicitly state that taking this medicine with Central Nervous System (CNS) depressants, such as certain sleeping pills (hypnotics), is highly risky. This combination significantly increases the risk of severe respiratory depression, profound sedation, and potentially coma.

Q: Are there any food or drink restrictions when using Codeintropfen-CT?

A: According to official administration instructions, the medicine can be taken with or without food. However, regulatory documents strictly state that alcohol must be avoided during the entire course of treatment due to the increased risk of severe central nervous system side effects.

Q: Is it safe to use Codeintropfen-CT while taking anti-anxiety medication?

A: Co-administration with other Central Nervous System (CNS) depressants, which includes many anti-anxiety medications, is listed as a serious interaction. This combination significantly increases the risk of severe respiratory depression, profound sedation, and other serious adverse outcomes.

Q: Does Codeintropfen-CT interact with any herbal supplements?

A: Official interaction warnings apply to any substance that might affect the CYP2D6 enzyme system in the liver. Regulatory documents state that patients should disclose all non-prescription and herbal supplements to their prescribing healthcare professional.

Q: Are there known interactions between Codeintropfen-CT and antidepressants?

A: Official warnings state that co-use with certain serotonergic medicines, which includes many antidepressants (like SSRIs or SNRIs), carries a specific risk. This combination may lead to the development of the serious condition known as Serotonin Syndrome.

Q: How long does it typically take for Codeintropfen-CT to start working for a cough?

A: Based on official pharmacokinetic data, the active substance reaches its peak concentration in the bloodstream approximately one hour after being taken orally. The cough-suppressing effect is expected to begin around this time.

Q: What is the maximum number of days Codeintropfen-CT is usually meant to be used?

A: The medicine is intended only for the short-term relief of symptoms. Official regulatory documents strictly mandate that the duration of use be limited to the minimum time required to treat the underlying condition, without specifying a fixed number of days.

Q: Is it expected that Codeintropfen-CT will completely stop the cough?

A: The medicine is classified as a cough suppressant (antitussive), which works to modulate the cough reflex. Official regulatory information also notes that studies on its efficacy have sometimes yielded conflicting results when compared to a placebo.

Q: What should be expected if my cough does not show improvement after several days of using Codeintropfen-CT?

A: Regulatory guidelines state that if symptoms persist or worsen after using the medicine for a short period, the regulatory guidelines require that the treatment be re-evaluated by a healthcare professional.

Q: Does the effect of Codeintropfen-CT last for the full time between scheduled uses?

A: Because the active substance has a relatively short half-life, the body processes it quickly. For the effect to be maintained, doses must be taken at the specified intervals (e.g., every four to eight hours) as prescribed on the label.

Q: What official regulatory warnings exist regarding the potential for misuse of Codeintropfen-CT?

A: Official documents contain warnings emphasizing the risk of abuse and dependence associated with the active ingredient. Due to this potential, regulatory agencies mandate the use of the lowest effective dosage for the shortest possible duration.

Q: What is the official risk classification of Codeintropfen-CT concerning abuse or dependence potential?

A: Codeine-containing products are classified as controlled substances under specific national and international drug schedules (e.g., Schedule II or III/V, depending on the country and concentration). This classification reflects the regulatory assessment of the potential for abuse and dependence.

Q: Can Codeintropfen-CT be used by someone with a diagnosed celiac disease or gluten sensitivity?

A: The official product label includes a complete list of inactive ingredients, or excipients, used in the liquid formulation. Patients are typically referred to the full excipient list or a pharmacist for confirmation of ingredient compatibility.

Q: Is the composition or effect of Codeintropfen-CT drops different from a tablet formulation, if one exists?

A: The liquid solution formulation is distinct in that it allows for precise dose titration (adjustment), which is generally not possible with fixed-dose tablets. Furthermore, the pharmacokinetic profile, such as the time it takes for the effect to begin, may differ between a liquid and a solid form.

Q: Does Codeintropfen-CT contain any sugar, sucrose, or artificial sweeteners?

A: The official product label includes a complete and detailed list of all inactive ingredients (excipients). This list specifies whether any sugars, sucrose, artificial sweeteners, or other flavoring agents are included in the liquid formulation.

Q: Where is the official expiration date located on the Codeintropfen-CT packaging or bottle?

A: Official guidelines mandate that the expiration date, often labelled as EXP, must be clearly printed in two locations: on the outer carton packaging and directly on the primary container or bottle label.

Q: What official warnings are provided about driving or operating heavy machinery while taking Codeintropfen-CT?

A: Regulatory documents explicitly caution that this medicine may cause side effects such as drowsiness, sedation, and dizziness. Due to these effects, the official warnings state that the medicine may impair the ability to drive or operate heavy machinery safely.

Q: Are there any known issues reported between Codeintropfen-CT use and existing eye conditions like glaucoma?

A: Regulatory documents advise caution for patients with pre-existing conditions that increase intracranial pressure or certain eye conditions like glaucoma, due to the specific effects of the opioid component.

Q: Does Codeintropfen-CT contain lactose or other common allergens?

A: The official product label is required to provide a complete list of inactive ingredients (excipients). This document confirms the presence or absence of substances like lactose or other common allergens in the formulation.

Q: What is the historical background of Codeintropfen-CT and when was it first approved?

A: The official regulatory history, including the initial date of approval for the active ingredient and formulation, is maintained by the approving government agency (such as the EMA or FDA). This document details the significant regulatory milestones of the medicine.

How should Codeintropfen-CT be stored and disposed of?

How to Store and Dispose of Codeintropfen-CT?

The official storage conditions require that the Codeintropfen-CT oral solution must be stored at a temperature not exceeding 25 C. The medicine should be kept in its original packaging, which affords protection from light. Due to the product's liquid nature, the regulatory label specifies a limited shelf-life of 6 months after the container has been opened.

Child Safety and Disposal

As a mandatory safety precaution, the medicinal product must be stored strictly out of the sight and reach of children. When the medicine is no longer needed or has expired, it must not be disposed of in household waste or flushed down the toilet/drain. Disposal must adhere to official pharmaceutical waste guidelines; users are instructed to consult their pharmacist for the correct method of discarding unused or expired product.

Codeintropfen-CT